Chair
Member
Audit Committee Position

Robert E. Ward

Mr. Ward brings to OncoSec over 30 years of experience as a global biopharmaceutical industry leader with experience across the full spectrum of drug development and commercialization. Mr. Ward currently serves as Chairman and Chief Executive Officer of Eloxx Pharmaceuticals. Prior to joining Eloxx, Mr. Ward was President and Chief Executive Officer of Radius Health, Inc., where he helped the company successfully complete its initial public offering and lead the development, approval and launch of the company's TYMLOS™ injection. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of Astra Zeneca. He has held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward currently serves as a Director of the Massachusetts High Technology Council and had served as a Director of Akari Therapeutics from October 2016 to August 2018.

Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.

Chair

Avtar Dhillon, M.D.

As former president and CEO of Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation), Dr. Dhillon successfully created a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon also raised over $125 million and secured more than $200 million in licensing deals from global companies including Merck and Wyeth (now Pfizer).

Dr. Dhillon was a founding board member of Protox Therapeutics, Inc. and currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.

Member

James M. DeMesa, M.D.

Dr. DeMesa has been a practicing physician and served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development. Most recently, Dr. DeMesa served as president, CEO, and director of Migenix Inc., a public biotechnology company.

Dr. DeMesa was also president and CEO of GenSci Regeneration Sciences Inc., a public biotech company, and vice president of medical and regulatory affairs at Biodynamics International, Inc. He is also a co-founder of CommGeniX and MedXcel.

Member

Margaret R. Dalesandro, Ph.D.

Dr. Dalesandro brings more than 25 years of drug development experience in the pharmaceutical, biotechnology and diagnostics industries.  She currently serves as the President of Brecon Pharma Consulting, a full-service pharmaceutical and biotech consultancy firm.  She previously served as Business Director of Corning Integrative Pharmacology.  Before that, Dr. Dalesandro held an executive leadership role at ImClone Systems where she oversaw project management for the clinical development of ERBITUX® (cetuximab), making significant contributions to the sale of ImClone to Eli Lilly in 2008.  Prior to that, Dr. Dalesandro served as an Executive Director at GlaxoSmithKline, managing cardiovascular, urology, and oncology drug product commercialization.  Earlier in her career, she was a senior consultant at Cambridge Pharma Consultancy and a Director of Immunobiology and Diagnostic Research at Centocor. 

Dr. Dalesandro holds a Ph.D. and M.A. in Biochemistry from Bryn Mawr College and an A.B. in Biology and Chemistry from Rosemont College, where she graduated summa cum laude.

Member

Audit Committee Charter

Download
Compensation Committee Position

Avtar Dhillon, M.D.

As former president and CEO of Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation), Dr. Dhillon successfully created a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon also raised over $125 million and secured more than $200 million in licensing deals from global companies including Merck and Wyeth (now Pfizer).

Dr. Dhillon was a founding board member of Protox Therapeutics, Inc. and currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.

Chair

James M. DeMesa, M.D.

Dr. DeMesa has been a practicing physician and served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development. Most recently, Dr. DeMesa served as president, CEO, and director of Migenix Inc., a public biotechnology company.

Dr. DeMesa was also president and CEO of GenSci Regeneration Sciences Inc., a public biotech company, and vice president of medical and regulatory affairs at Biodynamics International, Inc. He is also a co-founder of CommGeniX and MedXcel.

Member

Robert E. Ward

Mr. Ward brings to OncoSec over 30 years of experience as a global biopharmaceutical industry leader with experience across the full spectrum of drug development and commercialization. Mr. Ward currently serves as Chairman and Chief Executive Officer of Eloxx Pharmaceuticals. Prior to joining Eloxx, Mr. Ward was President and Chief Executive Officer of Radius Health, Inc., where he helped the company successfully complete its initial public offering and lead the development, approval and launch of the company's TYMLOS™ injection. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of Astra Zeneca. He has held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward currently serves as a Director of the Massachusetts High Technology Council and had served as a Director of Akari Therapeutics from October 2016 to August 2018.

Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.

Member

Margaret R. Dalesandro, Ph.D.

Dr. Dalesandro brings more than 25 years of drug development experience in the pharmaceutical, biotechnology and diagnostics industries.  She currently serves as the President of Brecon Pharma Consulting, a full-service pharmaceutical and biotech consultancy firm.  She previously served as Business Director of Corning Integrative Pharmacology.  Before that, Dr. Dalesandro held an executive leadership role at ImClone Systems where she oversaw project management for the clinical development of ERBITUX® (cetuximab), making significant contributions to the sale of ImClone to Eli Lilly in 2008.  Prior to that, Dr. Dalesandro served as an Executive Director at GlaxoSmithKline, managing cardiovascular, urology, and oncology drug product commercialization.  Earlier in her career, she was a senior consultant at Cambridge Pharma Consultancy and a Director of Immunobiology and Diagnostic Research at Centocor. 

Dr. Dalesandro holds a Ph.D. and M.A. in Biochemistry from Bryn Mawr College and an A.B. in Biology and Chemistry from Rosemont College, where she graduated summa cum laude.

Member

Compensation Committee Charter

Download
Nominating and Corporate Governance Committee Position

James M. DeMesa, M.D.

Dr. DeMesa has been a practicing physician and served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development. Most recently, Dr. DeMesa served as president, CEO, and director of Migenix Inc., a public biotechnology company.

Dr. DeMesa was also president and CEO of GenSci Regeneration Sciences Inc., a public biotech company, and vice president of medical and regulatory affairs at Biodynamics International, Inc. He is also a co-founder of CommGeniX and MedXcel.

Chair

Avtar Dhillon, M.D.

As former president and CEO of Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation), Dr. Dhillon successfully created a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon also raised over $125 million and secured more than $200 million in licensing deals from global companies including Merck and Wyeth (now Pfizer).

Dr. Dhillon was a founding board member of Protox Therapeutics, Inc. and currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.

Member

Robert E. Ward

Mr. Ward brings to OncoSec over 30 years of experience as a global biopharmaceutical industry leader with experience across the full spectrum of drug development and commercialization. Mr. Ward currently serves as Chairman and Chief Executive Officer of Eloxx Pharmaceuticals. Prior to joining Eloxx, Mr. Ward was President and Chief Executive Officer of Radius Health, Inc., where he helped the company successfully complete its initial public offering and lead the development, approval and launch of the company's TYMLOS™ injection. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of Astra Zeneca. He has held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward currently serves as a Director of the Massachusetts High Technology Council and had served as a Director of Akari Therapeutics from October 2016 to August 2018.

Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.

Member

Margaret R. Dalesandro, Ph.D.

Dr. Dalesandro brings more than 25 years of drug development experience in the pharmaceutical, biotechnology and diagnostics industries.  She currently serves as the President of Brecon Pharma Consulting, a full-service pharmaceutical and biotech consultancy firm.  She previously served as Business Director of Corning Integrative Pharmacology.  Before that, Dr. Dalesandro held an executive leadership role at ImClone Systems where she oversaw project management for the clinical development of ERBITUX® (cetuximab), making significant contributions to the sale of ImClone to Eli Lilly in 2008.  Prior to that, Dr. Dalesandro served as an Executive Director at GlaxoSmithKline, managing cardiovascular, urology, and oncology drug product commercialization.  Earlier in her career, she was a senior consultant at Cambridge Pharma Consultancy and a Director of Immunobiology and Diagnostic Research at Centocor. 

Dr. Dalesandro holds a Ph.D. and M.A. in Biochemistry from Bryn Mawr College and an A.B. in Biology and Chemistry from Rosemont College, where she graduated summa cum laude.

Member

Nominating and Corporate Governance Committee Charter

Download

Robert E. Ward

Mr. Ward brings to OncoSec over 30 years of experience as a global biopharmaceutical industry leader with experience across the full spectrum of drug development and commercialization. Mr. Ward currently serves as Chairman and Chief Executive Officer of Eloxx Pharmaceuticals. Prior to joining Eloxx, Mr. Ward was President and Chief Executive Officer of Radius Health, Inc., where he helped the company successfully complete its initial public offering and lead the development, approval and launch of the company's TYMLOS™ injection. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of Astra Zeneca. He has held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward currently serves as a Director of the Massachusetts High Technology Council and had served as a Director of Akari Therapeutics from October 2016 to August 2018.

Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.

Avtar Dhillon, M.D.

As former president and CEO of Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation), Dr. Dhillon successfully created a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon also raised over $125 million and secured more than $200 million in licensing deals from global companies including Merck and Wyeth (now Pfizer).

Dr. Dhillon was a founding board member of Protox Therapeutics, Inc. and currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.

James M. DeMesa, M.D.

Dr. DeMesa has been a practicing physician and served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development. Most recently, Dr. DeMesa served as president, CEO, and director of Migenix Inc., a public biotechnology company.

Dr. DeMesa was also president and CEO of GenSci Regeneration Sciences Inc., a public biotech company, and vice president of medical and regulatory affairs at Biodynamics International, Inc. He is also a co-founder of CommGeniX and MedXcel.

Margaret R. Dalesandro, Ph.D.

Dr. Dalesandro brings more than 25 years of drug development experience in the pharmaceutical, biotechnology and diagnostics industries.  She currently serves as the President of Brecon Pharma Consulting, a full-service pharmaceutical and biotech consultancy firm.  She previously served as Business Director of Corning Integrative Pharmacology.  Before that, Dr. Dalesandro held an executive leadership role at ImClone Systems where she oversaw project management for the clinical development of ERBITUX® (cetuximab), making significant contributions to the sale of ImClone to Eli Lilly in 2008.  Prior to that, Dr. Dalesandro served as an Executive Director at GlaxoSmithKline, managing cardiovascular, urology, and oncology drug product commercialization.  Earlier in her career, she was a senior consultant at Cambridge Pharma Consultancy and a Director of Immunobiology and Diagnostic Research at Centocor. 

Dr. Dalesandro holds a Ph.D. and M.A. in Biochemistry from Bryn Mawr College and an A.B. in Biology and Chemistry from Rosemont College, where she graduated summa cum laude.

Avtar Dhillon, M.D.

As former president and CEO of Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation), Dr. Dhillon successfully created a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon also raised over $125 million and secured more than $200 million in licensing deals from global companies including Merck and Wyeth (now Pfizer).

Dr. Dhillon was a founding board member of Protox Therapeutics, Inc. and currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.

James M. DeMesa, M.D.

Dr. DeMesa has been a practicing physician and served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development. Most recently, Dr. DeMesa served as president, CEO, and director of Migenix Inc., a public biotechnology company.

Dr. DeMesa was also president and CEO of GenSci Regeneration Sciences Inc., a public biotech company, and vice president of medical and regulatory affairs at Biodynamics International, Inc. He is also a co-founder of CommGeniX and MedXcel.

Robert E. Ward

Mr. Ward brings to OncoSec over 30 years of experience as a global biopharmaceutical industry leader with experience across the full spectrum of drug development and commercialization. Mr. Ward currently serves as Chairman and Chief Executive Officer of Eloxx Pharmaceuticals. Prior to joining Eloxx, Mr. Ward was President and Chief Executive Officer of Radius Health, Inc., where he helped the company successfully complete its initial public offering and lead the development, approval and launch of the company's TYMLOS™ injection. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of Astra Zeneca. He has held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward currently serves as a Director of the Massachusetts High Technology Council and had served as a Director of Akari Therapeutics from October 2016 to August 2018.

Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.

Margaret R. Dalesandro, Ph.D.

Dr. Dalesandro brings more than 25 years of drug development experience in the pharmaceutical, biotechnology and diagnostics industries.  She currently serves as the President of Brecon Pharma Consulting, a full-service pharmaceutical and biotech consultancy firm.  She previously served as Business Director of Corning Integrative Pharmacology.  Before that, Dr. Dalesandro held an executive leadership role at ImClone Systems where she oversaw project management for the clinical development of ERBITUX® (cetuximab), making significant contributions to the sale of ImClone to Eli Lilly in 2008.  Prior to that, Dr. Dalesandro served as an Executive Director at GlaxoSmithKline, managing cardiovascular, urology, and oncology drug product commercialization.  Earlier in her career, she was a senior consultant at Cambridge Pharma Consultancy and a Director of Immunobiology and Diagnostic Research at Centocor. 

Dr. Dalesandro holds a Ph.D. and M.A. in Biochemistry from Bryn Mawr College and an A.B. in Biology and Chemistry from Rosemont College, where she graduated summa cum laude.

James M. DeMesa, M.D.

Dr. DeMesa has been a practicing physician and served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development. Most recently, Dr. DeMesa served as president, CEO, and director of Migenix Inc., a public biotechnology company.

Dr. DeMesa was also president and CEO of GenSci Regeneration Sciences Inc., a public biotech company, and vice president of medical and regulatory affairs at Biodynamics International, Inc. He is also a co-founder of CommGeniX and MedXcel.

Avtar Dhillon, M.D.

As former president and CEO of Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation), Dr. Dhillon successfully created a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon also raised over $125 million and secured more than $200 million in licensing deals from global companies including Merck and Wyeth (now Pfizer).

Dr. Dhillon was a founding board member of Protox Therapeutics, Inc. and currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.

Robert E. Ward

Mr. Ward brings to OncoSec over 30 years of experience as a global biopharmaceutical industry leader with experience across the full spectrum of drug development and commercialization. Mr. Ward currently serves as Chairman and Chief Executive Officer of Eloxx Pharmaceuticals. Prior to joining Eloxx, Mr. Ward was President and Chief Executive Officer of Radius Health, Inc., where he helped the company successfully complete its initial public offering and lead the development, approval and launch of the company's TYMLOS™ injection. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of Astra Zeneca. He has held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward currently serves as a Director of the Massachusetts High Technology Council and had served as a Director of Akari Therapeutics from October 2016 to August 2018.

Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.

Margaret R. Dalesandro, Ph.D.

Dr. Dalesandro brings more than 25 years of drug development experience in the pharmaceutical, biotechnology and diagnostics industries.  She currently serves as the President of Brecon Pharma Consulting, a full-service pharmaceutical and biotech consultancy firm.  She previously served as Business Director of Corning Integrative Pharmacology.  Before that, Dr. Dalesandro held an executive leadership role at ImClone Systems where she oversaw project management for the clinical development of ERBITUX® (cetuximab), making significant contributions to the sale of ImClone to Eli Lilly in 2008.  Prior to that, Dr. Dalesandro served as an Executive Director at GlaxoSmithKline, managing cardiovascular, urology, and oncology drug product commercialization.  Earlier in her career, she was a senior consultant at Cambridge Pharma Consultancy and a Director of Immunobiology and Diagnostic Research at Centocor. 

Dr. Dalesandro holds a Ph.D. and M.A. in Biochemistry from Bryn Mawr College and an A.B. in Biology and Chemistry from Rosemont College, where she graduated summa cum laude.